Clinical trial
An Open-label, Multicenter Protocol Providing Pegylated Interferon Alfa-2a (Pegasys®) as Monotherapy or in Combination With Ribavirin (Copegus®) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
NCT01853254 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multicenter Protocol Providing Pegylated Interferon Alfa-2a (Pegasys®) as Monotherapy or in Combination With Ribavirin (Copegus®) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 30, 2003
- Completion date
- September 30, 2011
- Enrollment
- 272 (actual)
- Sites
- 67
Conditions
As the registry lists them; a condition with its own page is linked.